NGD 963
Alternative Names: NGD 96-3Latest Information Update: 17 Mar 2008
At a glance
- Originator Neurogen Corporation
- Developer Neurogen Corporation; Pfizer
- Class
- Mechanism of Action GABA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 11 Mar 2002 Phase-I clinical trials in Insomnia in USA (unspecified route)
- 09 Jan 2002 Preclinical development for Insomnia in USA (Unknown route)